Version history

{
  "session_id": "sess-hyp-9935d8a1fc17",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: Closed-Loop tACS Targeting EC-II SST Interneurons for AD\n\n## Executive Summary\n\nThis hypothesis proposes an innovative circuit-level intervention combining neuromodulation with a specific cellular target. However, I identify **critical gaps in target validation, technological specificity, and translation potential** that substantially limit confidence in near-term clinical translation. While the mechanistic rationale is intellectually coherent, the practical implementation faces formidable challenges.\n\n**Overall Confidence Score: 0.34**\n\n---\n\n## 1. TARGET DRUGGABILITY ASSESSMENT\n\n### Primary Target Identification\nThe hypothesis presents **two distinct target layers**:\n\n| Target Layer | Description | Druggable? | Confidence |\n|-------------|-------------|------------|------------|\n| **SST Interneuron Circuit** | Neural circuit modulation via tACS | Indirectly (device-based) | Low |\n| **HCN1 Channel Function** | Molecular restoration of channel trafficking | Theoretically (small molecules) | Moderate |\n| **SST Peptide/Receptors** | SST-SSTR signaling pathway | Yes (established pharmacology) | Not leveraged |\n\n### Critical Assessment\n\n**",
  "tokens_used": "293",
  "persona_id": "persona-domain_expert"
}